2015 - Member of Academia Europaea
His primary areas of investigation include Psoriasis, Internal medicine, Dermatology, Immunology and Surgery. Christopher E.M. Griffiths combines subjects such as Quality of life and Disease with his study of Psoriasis. His Internal medicine research incorporates elements of Gastroenterology, Placebo and Endocrinology.
Tretinoin and Negroid is closely connected to Chemotherapy in his research, which is encompassed under the umbrella topic of Dermatology. His studies in Surgery integrate themes in fields like Cohort study, Confidence interval and Ustekinumab. His study in Guselkumab is interdisciplinary in nature, drawing from both Etanercept and Risankizumab.
Psoriasis, Internal medicine, Dermatology, Immunology and Pathology are his primary areas of study. His study in Psoriasis focuses on Psoriasis Area and Severity Index in particular. His Psoriasis Area and Severity Index research is multidisciplinary, relying on both Dermatology Life Quality Index, Adverse effect and Severity of illness.
His Internal medicine study integrates concerns from other disciplines, such as Placebo, Endocrinology and Surgery. Christopher E.M. Griffiths works mostly in the field of Endocrinology, limiting it down to topics relating to Human skin and, in certain cases, Retinoic acid, as a part of the same area of interest. Christopher E.M. Griffiths has researched Dermatology in several fields, including Chemotherapy and MEDLINE.
His scientific interests lie mostly in Psoriasis, Internal medicine, MEDLINE, Psoriasis Area and Severity Index and Dermatology. The study incorporates disciplines such as Clinical trial, Intensive care medicine, Disease, Etanercept and Cohort in addition to Psoriasis. He usually deals with Disease and limits it to topics linked to General partnership and Systematic review and Nursing.
His MEDLINE research incorporates themes from Global health, Physiology, Seasonality and Circadian rhythm. His Psoriasis Area and Severity Index study combines topics in areas such as Odds ratio, Dermatology Life Quality Index, Adverse effect and Dosing. In his study, Gastroenterology is strongly linked to Moderate to severe, which falls under the umbrella field of Dermatology.
His primary scientific interests are in Psoriasis, Internal medicine, Psoriasis Area and Severity Index, Cohort and Ustekinumab. His study deals with a combination of Psoriasis and Systemic therapy. Christopher E.M. Griffiths interconnects Dermatology Life Quality Index, Bioinformatics, Transcriptome, Randomized controlled trial and Confidence interval in the investigation of issues within Psoriasis Area and Severity Index.
He combines subjects such as Placebo and Interleukin 17 with his study of Randomized controlled trial. The study incorporates disciplines such as Dermatology, Acrodermatitis, Therapeutic drug monitoring and Cohort study in addition to Cohort. His work focuses on many connections between Ustekinumab and other disciplines, such as Clinical trial, that overlap with his field of interest in Propensity score matching and Number needed to treat.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Pathogenesis and clinical features of psoriasis.
Christopher E. M. Griffiths;Jonathan N. W. N. Barker.
The Lancet (2007)
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G. Langley;Boni E. Elewski;Mark Lebwohl;Kristian Reich.
The New England Journal of Medicine (2014)
Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
Rosa Parisi;Deborah P.M. Symmons;Christopher E.M. Griffiths;Darren M. Ashcroft.
Journal of Investigative Dermatology (2013)
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis : a phase III, multicentre, double-blind trial
Kristian Reich;Frank O Nestle;Kim Papp;Jean-Paul Ortonne.
The Lancet (2005)
British guideline on the management of asthma: A national clinical guideline
Graham Douglas;Bernard Higgins;Neil Barnes;Anne Boyter.
Thorax (2008)
Psoriasis: epidemiology, clinical features, and quality of life
R G B Langley;G G Krueger;C E M Griffiths.
Annals of the Rheumatic Diseases (2005)
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E.M. Griffiths;Bruce E. Strober;Peter van de Kerkhof;Vincent Ho.
The New England Journal of Medicine (2010)
Keratinocytes as initiators of inflammation
Jonathan N. W. N. Barker;C. E. M. Griffiths;Brian J. Nickoloff;R. S. Mitra.
The Lancet (1991)
European S3-guidelines on the systemic treatment of psoriasis vulgaris
D Pathirana;AD Ormerod;P Saiag;Catherine Smith.
Journal of The European Academy of Dermatology and Venereology (2009)
A Genome-Wide Association Study Identifies New Psoriasis Susceptibility Loci and an Interaction Between HLA-C and ERAP1
Amy Strange;Francesca Capon;Chris C A Spencer.
Nature Genetics (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
King's College London
King's College London
University of Michigan–Ann Arbor
University of Manchester
University of Limerick
Manchester Academic Health Science Centre
Probity Medical Research
University of Manchester
University of Miami
Keele University
Johns Hopkins University
Griffith University
Google (United States)
Fred Hutchinson Cancer Research Center
University of Ulster
University of Southern California
Chinese Academy of Sciences
Universidade de São Paulo
University of Copenhagen
Goddard Space Flight Center
University of Florida
University of Bologna
University of Chicago
University of Edinburgh
University of Colorado Anschutz Medical Campus
University College London